June 9 news, Hong Kong stocks opened higher on Monday. On the market, most large technology stocks and pharmaceutical stocks rose. As of 15:00, the Hong Kong stock technology 50 ETF (513980) rose 1.83%, with a turnover of 741 million yuan. The highest intraday increase was more than 2%, and has risen more than 32% so far this year.
In terms of popular stocks, Kingsray Biotechnology rose by more than 15%, MaiFTSE, Sansheng Pharmaceuticals, Innovent Biologics rose by more than 8%, and Meituan-W, SMIC, BeiGene, Alibaba-W and other stocks followed suit.
Kingsrui Biotechnology (01548.HK): On the news, the pharmaceutical cube believes that under tariff anxiety, the United States is "rushing to buy" China's innovative drugs. In the past two years, the license-out wave has emerged, and multinational pharmaceutical companies have gradually established recognition and trust in China's innovative drugs and the "payment" of real money in the successive BD.
MaiFTSE (02556.HK):The company is a leader in the field of marketing and sales of SaaS. Combined with the accelerated integration of AI applications, it is expected to grow rapidly. On the news front, the company's controlling shareholder voluntarily extended the lock-up for one year to strengthen market confidence, and had all the negative news in the short term and severe stagflation. At the same time, the impact of tariff friction may be further weakened under the positive signal of the call between the Chinese and US dollar leaders, and market confidence is boosted; Hong Kong technology leading stocks have been adjusted for a period of time and have a higher cost-effectiveness. In addition, with the scarcity of leading technology targets, it is expected to benefit from the transformation of the AI industry, and the capital expenditure and cloud business revenue of leading Internet companies in Hong Kong stocks have also grown strongly.
Industry Biologics (01801.HK): On the news front, Industry Biologics verbally reported the latest phase clinical data of IBI363 in non-small cell lung cancer (NSCLC), colon cancer (CRC) and melanoma at the ASCO annual meeting. Goldman Sachs published a research report pointing out that compared with the abstract, the research data are more positive for objective response rate (ORR) and progression-free survival (PFS) data, especially in immunotherapy-treated squamous cell/adenocancer NSCLC, giving it a "buy" rating; at the same time, JPMorgan Chase raised its target price and reiterated its overweight rating.
In terms of net inflow of funds, Wind data statistics show that as of the latest closing date, the Hong Kong Stock Technology 50ETF (513980) has a net inflow of 4.687 billion yuan in the past three months, and the net inflow of 6.205 billion yuan from the beginning of the year to the present.
Huafu Securities pointed out that as of 2037, 27 drugs with global sales of more than US$4 billion in 2024 will face a patent cliff in the United States. Therefore, multinational pharmaceutical companies (MNCs) are eager to find blockbuster innovative drugs. Galaxy Securities also stated that the pharmaceutical market will usher in a continuous recovery, and structural opportunities still exist. From the perspective of short-term and medium- and long-term definite growth, we are optimistic about the continued good performance of the innovative drug industry chain this year.
Industry Securities said that the main market line in June is expected to be biased towards technological growth again. Recently, it has been observed that the growth sector has been "restless" from the bottom. Judging from the current indicators such as congestion, rolling income difference, transaction proportion, and calendar effect, the position of the technology sector has risen from the bottom recently, and the overall performance-oriented is still in the cost-effective range. It is recommended to take the AI industry chain as a starting point and pay attention to the independent controllable computing power and the innovation of mid- and downstream application.
Editor: Hou Yijun
